Sodium oxybate assigned Controlled Drug status

Sodium oxybate (Xyrem) was reclassified as a Schedule 2 Controlled Drug (CD POM) on January 7 and is now subject to prescription writing, requisition, destruction and safe custody requirements. Xyrem is indicated for the treatment of narcolepsy with cataplexy.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Macrolide prescribing in pregnancy linked to risk of birth defects

Macrolide prescribing in pregnancy linked to risk of birth defects

Researchers have called for caution when prescribing...

NICE overturns advice to increase steroid dose in children with asthma

NICE overturns advice to increase steroid dose in children with asthma

NICE has withdrawn its recommendation to quadruple...

New antibiotic guidance for leg ulcer infection

New antibiotic guidance for leg ulcer infection

NICE has issued guidance on antibiotic choices and...